First Tracks Biotherapeutics (NASDAQ:TRAX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS

First Tracks Biotherapeutics (NASDAQ:TRAX) posted its quarterly earnings results on Wednesday. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.21), Zacks reports.

First Tracks Biotherapeutics Stock Performance

Shares of TRAX stock traded down $0.87 on Friday, reaching $43.16. The stock had a trading volume of 83,592 shares, compared to its average volume of 633,860. First Tracks Biotherapeutics has a 1 year low of $14.72 and a 1 year high of $49.91. The firm has a market cap of $1.51 billion and a PE ratio of -23.45. The stock’s 50 day simple moving average is $29.84.

Wall Street Analyst Weigh In

Several research firms recently commented on TRAX. Wells Fargo & Company increased their price objective on First Tracks Biotherapeutics from $30.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th. HC Wainwright upped their target price on shares of First Tracks Biotherapeutics from $44.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler raised their price target on shares of First Tracks Biotherapeutics from $54.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Barclays boosted their price objective on shares of First Tracks Biotherapeutics from $48.00 to $65.00 and gave the company an “overweight” rating in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.50.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.